As PD-L1 expression is enriched on the surface of tumor cells in patients with ESCC [11], Immune checkpoint inhibitors (ICIs) directed at PD-1 and its counterpart PD-L1 have displayed encouraging outcomes in the management of advanced ESCC. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.